Key takeaways
- Tirzepatide is a single peptide, based on the sequence of the hormone GIP, that activates both the GIP and GLP-1 receptors; a C-20 fatty diacid side chain lets it bind albumin, a blood protein.
- Eli Lilly sells it as Mounjaro (US approval May 2022, for type 2 diabetes) and Zepbound (November 2023, for weight management in adults with obesity, or overweight with a weight-related condition); Zepbound added obstructive sleep apnoea in December 2024 and Mounjaro a cardiovascular use in August 2026.
- Both US labels carry a boxed warning: in rats tirzepatide causes thyroid C-cell tumours, and whether it does so in humans is unknown. The labels also warn of pancreatitis, gallbladder disease, kidney injury and severe gastrointestinal reactions.
- In SURPASS-CVOT, 13,299 adults with type 2 diabetes and cardiovascular disease, tirzepatide was no worse than dulaglutide on cardiovascular death, heart attack or stroke; the label says superiority “was not established”.
- FDA declared the US tirzepatide shortage resolved on 19 December 2024, after a first decision in October 2024 was reconsidered; its grace period for compounded copies ended for outsourcing facilities on 19 March 2025.
01What is tirzepatide?
Tirzepatide is a single peptide that activates the receptors for two gut hormones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Its US label calls it a “GIP receptor and GLP-1 receptor agonist” that “selectively binds to and activates both the GIP and GLP-1 receptors”. Papers call it a dual agonist. Eli Lilly developed it under the code LY3298176. Lilly’s retatrutide, an investigational drug and not an approved medicine, is a single peptide that activates the receptors for three hormones, GIP, GLP-1 and glucagon. How tirzepatide differs from semaglutide: semaglutide vs tirzepatide.
How it is built. The label says tirzepatide “is based on the GIP sequence”. It carries aminoisobutyric acid (Aib) at positions 2 and 13, an amide at its end, and a lysine at position 20 linked to a C-20 fatty diacid (1,20-eicosanedioic acid) that lets it bind albumin, a blood protein.
| Question | Tirzepatide |
|---|---|
| What it is | A GIP receptor and GLP-1 receptor agonist; formula C225H348N48O68, 4813.53 Da (US label) |
| Maker and brands | Eli Lilly: Mounjaro and Zepbound |
| Status | Prescription medicine in the US and the UK; centrally authorised in the EU; Schedule 4 (Prescription Only Medicine) in Australia |
| Boxed warning (US) | Thyroid C-cell tumours in rats; whether this happens in humans is unknown |
| Sport | On WADA’s 2027 Monitoring Program; not named on the 2027 Prohibited List |
Research-grade material sold as “tirzepatide” is not Mounjaro or Zepbound. Nothing on this page describes it.
02Where is tirzepatide approved, and for what?
Regulators approve products, not molecules. Dates and uses come from each regulator’s records, checked on 18 November 2026.
| Market | Products | What the labels cover |
|---|---|---|
| United States | Mounjaro (13 May 2022), Zepbound (8 Nov 2023) | Mounjaro: blood sugar control in type 2 diabetes, in adults and, on the current label, children 10 and older; lower risk of cardiovascular death, heart attack or stroke in adults with type 2 diabetes at high risk (27 Aug 2026). Zepbound: reducing excess body weight in adults with obesity, or overweight with a weight-related condition (8 Nov 2023); moderate to severe obstructive sleep apnoea in adults with obesity (20 Dec 2024) |
| European Union | Mounjaro (15 Sep 2022) | Type 2 diabetes in adults, adolescents and children 10 and older; weight management in adults. Trial results in obstructive sleep apnoea and in heart failure with preserved ejection fraction are described in the product information, not listed as separate uses |
| United Kingdom | Mounjaro | Type 2 diabetes, including children 10 and older; weight management in adults, authorised by the MHRA on 8 Nov 2023 through a national route. Listed as a prescription-only medicine (POM) |
| Australia | Mounjaro (on the ARTG 23 Dec 2022) | Type 2 diabetes from 23 Dec 2022; chronic weight management added on 10 Sep 2024. Tirzepatide is in Schedule 4 of the Poisons Standard October 2026 |
Material sold as tirzepatide for research use is none of these products. Peptide law by market: US, UK, Australia.
03What do the tirzepatide labels warn about?
Boxed warning. Both US labels open with it: “In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.” Whether it causes these tumours in humans, including medullary thyroid carcinoma, is unknown; the labels say their human relevance “has not been determined”. The medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2.
Warnings. The Zepbound label (August 2026) lists severe gastrointestinal reactions, acute kidney injury from fluid loss, gallbladder disease, acute pancreatitis, allergic reactions, hypoglycaemia, diabetic retinopathy complications in type 2 diabetes, and pulmonary aspiration during anaesthesia or deep sedation. Acute pancreatitis, “including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or ZEPBOUND”. The most common adverse reactions are led by nausea, diarrhoea, vomiting, constipation and abdominal pain.
After approval. The labels list reports of necrotizing pancreatitis “sometimes resulting in death”, intestinal obstruction, anaphylaxis, and acute renal failure “sometimes requiring hemodialysis”; because such reports are voluntary, it is not always possible to estimate how often they happen or whether the drug caused them. In January 2026 the MHRA said the UK product information for GLP-1 and dual GLP-1/GIP medicines, tirzepatide included, had been updated on severe acute pancreatitis, “including rare reports of necrotising and fatal pancreatitis”.
In the trials. In SURMOUNT-1, adverse events led 4.3% to 7.1% of people on the three tirzepatide levels to stop treatment, against 2.6% on placebo. In SURPASS-CVOT, “more gastrointestinal adverse events were observed in the tirzepatide group” than with dulaglutide. How to read safety data: side effects, documented and unknown. To report one: report a reaction.
04Which trials stand behind the tirzepatide labels?
Eli Lilly funded each trial below. SURPASS trials studied type 2 diabetes; SURMOUNT trials studied obesity. We give the design and what the label or paper reports for the primary measure.
| Trial and paper | Who took part, and for how long | Primary measure | What the label reports |
|---|---|---|---|
| SURPASS-1 · Lancet, 2021 | 478 adults with type 2 diabetes managed by diet and exercise alone; three tirzepatide levels or placebo; 40 weeks | Change in HbA1c, a measure of average blood sugar | Mounjaro label: effectiveness “established in five trials” (SURPASS-1 to -5), with “a statistically significant reduction from baseline in HbA1c compared to placebo” |
| SURMOUNT-1 · NEJM, 2022 | 2,539 adults with obesity, or overweight with a weight-related condition, without diabetes; three tirzepatide levels or placebo; 72 weeks | Percentage change in body weight, and the share losing at least 5% | Zepbound label: “a statistically significant reduction in body weight compared with placebo” |
| SURMOUNT-OSA · NEJM, 2024 | 469 adults with obesity and moderate to severe obstructive sleep apnoea, in two trials (with and without positive airway pressure therapy); 52 weeks | Change in the apnoea–hypopnoea index, the number of breathing pauses and shallow breaths per hour of sleep | Zepbound label: “a statistically significant reduction in AHI compared with placebo” |
| SURPASS-CVOT · NEJM, 2025 | 13,299 adults with type 2 diabetes and cardiovascular disease; tirzepatide or dulaglutide, an approved GLP-1 medicine; median 210 weeks | Cardiovascular death, heart attack or stroke; designed to show tirzepatide was no worse than dulaglutide | No worse than dulaglutide; hazard ratio 0.92 (95.3% CI 0.83 to 1.01). The label: “Superiority to dulaglutide was not established” |
Each result holds for the people, product and follow-up studied. The SURMOUNT-OSA paper carries a published correction (NEJM, October 2024), so we quote the label for it. How we grade evidence: evidence grades.
05What happened to compounded tirzepatide in the US?
FDA limits compounded copies of an approved drug; the limits relax while the drug is on FDA’s shortage list. Tirzepatide was listed from 2022. Its exit took two decisions.
FDA determined the tirzepatide shortage “has been resolved”. In litigation, the decision was sent back to FDA for reevaluation.
After reevaluating, FDA issued “a new decision determining the tirzepatide injection shortage is resolved”.
The end dates FDA set for state-licensed pharmacies (section 503A, or a court ruling if later) and for outsourcing facilities (section 503B). The court denied a preliminary injunction on 5 March 2025, and FDA said the 503A period “has ended”.
FDA: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
FDA on compounded tirzepatide. Compounded drugs “are not FDA approved”, and FDA does not review them for safety, effectiveness or quality before they are sold. By 31 May 2026 FDA had more than 730 adverse-event reports for compounded tirzepatide. It says many resemble those for the approved versions, that the true number is likely higher because state-licensed pharmacies that are not outsourcing facilities do not have to report, and that “It is not always possible to determine if the adverse event directly resulted from use of the drug”. FDA has also received reports of adverse events that may relate to compounded tirzepatide used in amounts beyond the approved label, some of them serious. It describes fraudulent compounded tirzepatide labelled with pharmacies that do not exist or did not make it, and one adverse-event report linked to such a product.
06What have regulators said about fake and research-labelled tirzepatide?
United Kingdom. In February 2026 the MHRA said fake Mounjaro had been dispensed by one private pharmacy in Birmingham, and contacted patients who may have received it. Testing found tirzepatide in it, but “because the manufacturing conditions are unknown, we cannot confirm that the contents are sterile”. On 14 October 2026 the MHRA and West Midlands Police seized more than 12,000 fake retatrutide and tirzepatide products at an industrial unit in Birmingham.
United States. FDA’s GLP-1 page (content current 1 October 2026) says the agency “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.
A lab report shows what one tested sample contained. It cannot make that sample Mounjaro or Zepbound. More: contamination and mislabeling.
07What we don’t know
- Whether tirzepatide causes thyroid C-cell tumours in humans. The labels say the human relevance of the rat finding “has not been determined”.
- Whether tirzepatide lowers cardiovascular events more than dulaglutide. SURPASS-CVOT showed it was no worse; “Superiority to dulaglutide was not established”.
- How it affects athletes. WADA kept the status of GLP-1 receptor agonists, tirzepatide named among them, unchanged for 2027 “pending further data becoming available on the possible effects on athletes who take them”.
- What any product sold outside the licensed supply chain contains. FDA calls research-labelled tirzepatide “of unknown quality”, and the MHRA could not confirm the sterility of fake Mounjaro it tested.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.